England and Wales reject Leo Pharma's eczema drug
The National Institute for Health and Care Excellence (NICE) has decided not to recommend Leo Pharma’s atopic dermatitis treatment tralokinumab.
by ulrich quistgaard, translated by daniel pedersen
The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), has announced in a press release that it does not recommend Leo Pharma’s Adtralza (tralokinumab) as a treatment for atopic dermatitis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
